Steven Cohen’s Denali Therapeutics DNLI Stock Holding History

Steven Cohen’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597K	Buy	23,200 +600	+3%	+$12.3K	﹤0.01%	3100
2026 Q1	$434K	Buy	+22,600	New	+$450K	﹤0.01%	3180

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's DNLI Position: Q1 2026 in Review

Steven Cohen sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 1,700,000 shares — an estimated $33.8M sold.

Steven Cohen first reported a position in DNLI in Q3 2022 and held it in 10 quarters. The position peaked at $36.6M in Q3 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Steven Cohen reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 1,700,000 Denali Therapeutics shares in Q1 2026, an estimated $33.8M.
Steven Cohen first reported a position in Denali Therapeutics in Q3 2022 and held it in 10 quarters.
Steven Cohen's Denali Therapeutics position peaked at $36.6M in Q3 2025.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.